SCHEMBL873754

SCHEMBL873754

CCC(O)OC(=O)c1ccccc1C(=O)OC

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.50
LMNA P02545 2/20 0.50
ALDH1A1 P00352 4/20 0.49
HSD17B10 Q99714 2/20 0.49
CFTR P13569 1/20 0.49
KMT2A Q03164 1/20 0.47
KDM4E B2RXH2 2/20 0.47
POLB P06746 2/20 0.47
ATM Q13315 1/20 0.47
GAA P10253 1/20 0.46
GLA P06280 1/20 0.45
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA5A P35218 1/20 0.44
CA9 Q16790 1/20 0.44
MAPT P10636 1/20 0.44
ALOX15 P16050 1/20 0.44
MYC P01106 1/20 0.42
SLC6A3 Q01959 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ether SCHEMBL5610312 0.94 TSHR (0.46) TSHRLMNAALDH1A1HSD17B10CFTR
SCHEMBL1513963 0.93 TSHR (0.53) TSHRLMNAALDH1A1HSD17B10KMT2A
SCHEMBL1513969 0.86 ALDH1A1 (0.56) TSHRLMNAALDH1A1HSD17B10KMT2A
SCHEMBL10591636 0.86 TSHR (0.52) TSHRLMNAALDH1A1HSD17B10KDM4E
SCHEMBL28699777 0.85 TSHR (0.70) TSHRLMNAALDH1A1HSD17B10KDM4E
SCHEMBL28362466 0.83 LMNA (0.55) TSHRLMNAALDH1A1HSD17B10KMT2A
SCHEMBL27637585 0.83 SMN1; SMN2 (0.48) TSHRLMNAALDH1A1HSD17B10KMT2A
SCHEMBL27583153 0.83 UTS2R (0.48) TSHRLMNAALDH1A1HSD17B10KMT2A
SCHEMBL3110030 0.81 ALDH1A1 (0.60) TSHRALDH1A1HSD17B10CFTRKMT2A
SCHEMBL11329828 0.81 PTPN2 (0.43) TSHRLMNAALDH1A1HSD17B10KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 212 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3697389-B1 SUSTAINED RELEASE FORMULATIONS OF CROCUS SATIVUS COUNCIL SCIENT IND RES (IN) 2025-08-20 EP claimed
US-20250242031-A1 POLYMER SALTS FOR IMPROVED DRUG DELIVERY FROM AMORPHOUS SOLID DISPERSIONS PURDUE RESEARCH FOUNDATION 2025-07-31 US claimed
EP-4479092-A1 POLYMER SALTS FOR IMPROVED DRUG DELIVERY FROM AMORPHOUS SOLID DISPERSIONS Purdue Research Foundation (US) 2024-12-25 EP claimed
WO-2023154171-A1 POLYMER SALTS FOR IMPROVED DRUG DELIVERY FROM AMORPHOUS SOLID DISPERSIONS PURDUE RESEARCH FOUNDATION (US) 2023-08-17 WO claimed
US-20200390843-A1 SUSTAINED RELEASE FORMULATIONS OF CROCUS SATIVUS COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2020-12-17 US claimed
US-10758490-B2 Nanocapsules containing microemulsions LIPOTEC, S.A. (ES) 2020-09-01 US claimed
EP-3697389-A1 SUSTAINED RELEASE FORMULATIONS OFCROCUS SATIVUS Council of Scientific and Industrial Research (IN) 2020-08-26 EP claimed
CN-104783123-B Prebiotics low sodium salt and preparation method thereof 四川亿生元科技有限公司 2020-03-27 CN claimed
CN-110772647-A Capsule for carrying medicine for iodic contrast and preparation method thereof 河北医科大学 2020-02-11 CN claimed
EP-2618926-B1 NANOCAPSULES CONTAINING MICROEMULSIONS LIPOTEC SA (ES) 2019-05-08 EP claimed
WO-2005089720-A1 VALSARTAN TABLETS AND THE PROCESS FOR THE PREPARATION THEREOF RANBAXY LABORATORIES LIMITED (IN) 2005-09-29 WO claimed
WO-2005082330-A2 CO-PRECIPITATED AMORPHOUS CEFDITOREN PIVOXIL AND DOSAGE FORMS COMPRISING THE SAME RANBAXY LABORATORIES LIMITED (IN) 2005-09-09 WO claimed
EP-1545473-A2 MODIFIED RELEASE, MULTIPLE UNIT DRUG DELIVERY SYSTEMS RANBAXY LABORATORIES, LTD. (IN) 2005-06-29 EP claimed
WO-2003103637-A2 MODIFIED RELEASE, MULTIPLE UNIT DRUG DELIVERY SYSTEMS RANBAXY LABORATORIES LIMITED (IN) 2003-12-18 WO claimed
EP-1185250-A2 ENTERIC COATED PHARMACEUTICAL FORMULATION NORTON HEALTHCARE LIMITED (GB) 2002-03-13 EP claimed
EP-1119348-A2 ENTERIC COATED PHARMACEUTICAL FORMULATION NORTON HEALTHCARE LIMITED (GB) 2001-08-01 EP claimed
WO-2001051031-A2 ENTERIC COATED PHARMACEUTICAL FORMULATION NORTON HEALTHCARE LTD. (GB) 2001-07-19 WO claimed
WO-2000001363-A2 ENTERIC COATED PHARMACEUTICAL FORMULATION NORTON HEALTHCARE LTD. (GB) 2000-01-13 WO claimed
EP-0391518-B1 SUSTAINED-RELEASE PHARMACEUTICAL PREPARATION KINAFORM TECHNOLOGY, INC. (US) 1993-09-29 EP claimed
EP-0457919-A1 FUNCTIONAL FOOD KABUSHIKI KAISYA ADVANCE (JP) 1991-11-27 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250242031-A1 POLYMER SALTS FOR IMPROVED DRUG DELIVERY FROM AMORPHOUS SOLID DISPERSIONS SRI, SYNGR2, PSD TSHR 4586/4885LMNA 3397/4885ALDH1A1 3898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.